Published on 02/12/2025

Peer Review Checklists for Model Evidence in AI/ML Model Validation

Introduction to AI/ML Model Validation in GxP Analytics

In recent years, the incorporation of artificial intelligence (AI) and machine learning (ML) in Good Practice (GxP) analytics has brought a wave of innovations in pharmaceutical development and clinical research. However, the validation of these AIs and ML models is critical to ensure compliance with regulatory standards set by authorities such as the FDA, EMA, MHRA, and the guidelines provided by organizations like GAMP 5.

This guide delineates a comprehensive peer review checklist for model evidence encompassing the key aspects of model verification and validation (V&V), intended use, data readiness, explainability (XAI), and monitoring. The focus is on aligning with regulatory expectations while ensuring that the intended risks associated with model deployment are mitigated.

Step 1: Define the Intended Use and Model Risk Assessment

The first step in the AI/ML model validation process involves a clear and detailed definition of the model’s intended use along with a risk assessment. Understanding how the model will be used within the GxP context is essential for establishing the validation framework.

• Clarifying Intended Use: Document the specific applications of the AI/ML model, outlining the tasks it is designed to perform, such as predicting clinical outcomes, optimizing treatment paths, or analyzing drug efficacy.
• Assessing Intended Use Risk: Conduct a thorough risk analysis. Identify risks related to incorrect predictions, data integrity issues, and societal impacts including bias and fairness testing. Specify the potential consequences of these risks and their impact on patient safety and regulatory compliance.

Utilizing a detailed documentation process is essential for maintaining an audit trail and ensuring full transparency throughout the risk assessment phase. This aligns with 21 CFR Part 11 and Annex 11 regulations ensuring electronic records and signatures are trustworthy and reliable.

Step 2: Establish Data Readiness and Curation Protocols

Data readiness is a fundamental aspect of AI/ML model validation. The quality and integrity of the data used directly affect the performance and reliability of the model’s outputs. The following steps should be adhered to when preparing data:

• Data Collection: Ensure that the data collected is a representative sample of the population that the model is intended to serve. Gather historical data as well as real-time data if applicable.
• Data Cleaning and Preprocessing: Conduct thorough data hygiene checks to eliminate duplicates, irrelevant information, and errors. This may include normalizing formats, handling missing values, and ensuring consistency in variables.
• Data Annotation: Annotations are particularly important for supervised learning models. Accurate labeling is crucial to ensure the model learns appropriately from the datasets.
• Bias and Fairness Testing: Perform an analysis to identify any biases present in the data that could affect model outcomes. Establish fairness standards relevant to the intended demographic and application.

Documenting data readiness procedures establishes a robust foundation for model training and evaluation, facilitating transparency and accountability throughout the validation process.

Step 3: Verify Model Performance and Document Results

After ensuring that the data is ready for use, the next step is to execute the model and verify its performance. This involves rigorous testing against predefined benchmarks. Verification procedures should be systematically carried out:

• Model Training: Train the model using the curated dataset and apply established machine learning techniques. It is essential to utilize appropriate algorithms that align with the intended application.
• Performance Metrics Establishment: Select relevant performance metrics, such as accuracy, precision, recall, F1 score, and ROC/AUC, to evaluate the model. Depending upon the intended use, different metrics may take precedence.
• Validation Techniques: Implement cross-validation and testing against a separate validation set to mitigate overfitting. Perform sensitivity analysis to gauge stability under varying conditions.
• Documentation: Maintain detailed records of all performance outcomes, methodologies employed, and any deviations from expected results. Such documentation supports compliance with regulatory expectations.

It is advisable to employ version control mechanisms for developed models to facilitate traceability and re-evaluation. Regulatory bodies often prioritize transparency in validations, thus ensuring proper documentation aligns with their requirements.

Step 4: Explainability and Transparency in AI/ML Models

Explainability (XAI) has become an essential component in the deployment of AI/ML models, especially within regulated environments. Understanding and interpreting model behavior contributes to decision-making and trust-building among stakeholders.

• Adopt Explainable AI Techniques: Implement XAI methods, such as LIME or SHAP, to analyze the model’s predictions and the reasoning behind them. It is important for end-users to understand how decisions are made.
• Create User-Friendly Documentation: Provide clear documentation that outlines how the model functions, the variables used in prediction, and how results should be interpreted. This is crucial for regulatory submissions and audits.
• Stakeholder Engagement: Involve relevant stakeholders in the review of model outputs and explanations. Their insights can enhance the understanding of risks and benefits associated with model applications.

Achieving clarity on model outputs not only meets regulatory requirements but also promotes user confidence, crucial in environments dealing with life-saving therapies.

Step 5: Implement Drift Monitoring and Re-Validation Protocols

Once a model has been validated and deployed, continuous monitoring is necessary to ensure its alignment with intended functions over time. Model drift can occur due to changes in data patterns, necessitating regular re-evaluation.

• Drift Monitoring Procedures: Implement systems for continuous data tracking and model performance monitoring. Identify deviation thresholds for performance metrics that trigger alerts for re-evaluation.
• Scheduled Re-Validation: Define timelines for periodic re-validation of models in compliance with GAMP 5 guidelines. This includes reassessing the data, model assumptions, and performance against original benchmarks.
• Feedback Loops: Establish feedback mechanisms for capturing real-world outcomes and integrating them back into the validation cycle. This helps identify potential areas for enhancement or adjustment of model algorithms.

Proactive monitoring and systematic re-validation ensure the model continues to perform reliably in a changing environment, safeguarding patient outcomes while fulfilling regulatory mandates.

Step 6: Documentation and Audit Trails for Compliance

Comprehensive documentation is essential throughout the AI/ML model validation process. Regulatory bodies require clear evidence of compliance with established guidelines. Good documentation practices include:

• Creating Validation Plans: Outline the scope, approach, and specific methodologies to be followed during validation. Ensure alignment with organizational policies and regulatory directives.
• Maintaining Audit Trails: Employ systems that document every change made to the model, including data alterations and model parameter adjustments. This ensures traceability and accountability.
• Formal Review and Approval Process: Implement an approval system for validation documents and methodologies. Stakeholder reviews serve to validate compliance and ensure alignment with project goals.

Maintaining and reviewing documentation serves not only regulatory requirements but also enhances organizational integrity when communicating the model’s reliability and safety records.

Conclusion: Ensuring Comprehensive Model Validation

The validation of AI/ML models within GxP analytics is a multifaceted and rigorous process requiring due diligence in terms of methodology, documentation, and compliance. By adhering to a structured approach — from defining intended use and conducting risk assessments to ensuring data readiness and implementing continuous monitoring protocols — pharmaceutical organizations can significantly mitigate risks associated with model deployment.

Ultimately, integrating robust peer review checklists enhances the validation process, establishes confidence in AI/ML model outcomes, and complies with regulatory standards such as those outlined by EMA. Continuous improvement and adaptation of validation procedures will ensure sustainable AI governance and security, leveraging the full potential of technology in advancing pharmaceutical sciences.